NRx Pharmaceuticals Statistics
Share Statistics
NRx Pharmaceuticals has -
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | 0.67% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 840 |
| FTD / Avg. Volume | 6.09% |
Short Selling Information
The latest short interest is 1.6K, so 0% of the outstanding
shares have been sold short.
| Short Interest | 1.6K |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.92 and the forward
PE ratio is null.
NRx Pharmaceuticals's PEG ratio is
0.02.
| PE Ratio | -0.92 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | -1 |
| P/FCF Ratio | -2.18 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for NRx Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15,
with a Debt / Equity ratio of -0.28.
| Current Ratio | 0.15 |
| Quick Ratio | 0.15 |
| Debt / Equity | -0.28 |
| Debt / EBITDA | -0.36 |
| Debt / FCF | -0.62 |
| Interest Coverage | -80.44 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 8.04% in the
last 52 weeks. The beta is 1.45, so NRx Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 1.45 |
| 52-Week Price Change | 8.04% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.1 |
| Relative Strength Index (RSI) | 53.82 |
| Average Volume (20 Days) | 13,788 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -18.5M |
| Net Income | -25.13M |
| EBITDA | -18.5M |
| EBIT | -24.9M |
| Earnings Per Share (EPS) | -2.39 |
Full Income StatementBalance Sheet
The company has 1.44M in cash and 6.58M in
debt, giving a net cash position of -5.13M.
| Cash & Cash Equivalents | 1.44M |
| Total Debt | 6.58M |
| Net Cash | -5.13M |
| Retained Earnings | -278.27M |
| Total Assets | 7.59M |
| Working Capital | -25.5M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -10.64M
and capital expenditures 0, giving a free cash flow of -10.64M.
| Operating Cash Flow | -10.64M |
| Capital Expenditures | n/a |
| Free Cash Flow | -10.64M |
| FCF Per Share | -1.01 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
